C. Rubina Reichal, Christa Roshan Pius, S. Manju, M. Shobana
Dr. C. Rubina Reichal*, Christa Roshan Pius, S. Manju, M. Shobana
Professor, Assistant Professor, Department of Pharmaceutics, Cherraan’s College of Pharmacy, Coimbatore-39, India.
Volume - 14,
Issue - 2,
Year - 2021
The core objective of the present study was to formulate and characterize Gliclazide nanosuspension by using different polymers to improve the solubility and bioavailability of a drug. The formulation of Gliclazide Nanosuspension was done by the Nano precipitation method. The formulations were prepared by different polymers and surfactants. The formed nanosuspension was clear and no sedimentation on shaking. The Gliclazide formulation showed maximum solubility in HPMC. The preformulation parameters were evaluated like solubility, identification of sample by UV spectroscopy, FTIR studies. The viscosity of the dispersion medium was in F5 0.89m Pa-s, the zeta potential value was found to be -20.5mv. The SEM studies showed that the nanoparticles had a smooth surface. All the fabricated Gliclazide Nanosuspension were subjected to In vitro drug release, in this F5 which showed the highest % of drug release. The optimized formulation (F5) was compared with the marketed sample which has the same release pattern. The release kinetics confirmed that the optimized formulation followed zero-order kinetics. From this study, it has been concluded that the modified liquid dosage form complies the patient compliance and it is suitable for dose titration therapy in diabetes treatment.
Cite this article:
C. Rubina Reichal, Christa Roshan Pius, S. Manju, M. Shobana. Formulation and Characterization of Gliclazide Nanosuspension. Research J. Pharm. and Tech. 2021; 14(2):779-786. doi: 10.5958/0974-360X.2021.00136.0
1. Essentials of Pathophysiology. 2nd edition, Carol Mattson Porth, RN, MSN, Ph. D. Lippincott Williams and Wilkins, P(705-708).
2. Pooja A. Birade, Vaishali A.Kilor, Formulation and Evaluation ofGlimepiride Nanosuspension using Simple High Shera Homogenizer at Lab Scale IJPPR Vol.14(1) 2018: 20-29.
3. Gina S. EL-Feky, Gamal Zayed, Abdel Razik.H.Farrag, Optimization of An Ocular Nanosuspension Formulation for Acyclovir using Factorial Design, Int. J. Pharm. Pharm Sci, Vol5(1) 2013, 213-219.
4. Chowdary KPR, Madhavi BLR. Novel drug delivery technologies for insoluble drugs. Ind Drugs 2005;42:557-63.
5. Smita S. Aher, Sagar T. Malsane, R. B. Saudagar. Nano suspension: An Overview. Asian J. Res. Pharm. Sci. 2017; 7(2):81-86.
6. Vijay Shinde*, P Amsa, S Tamizharasi, D Karthikeyan, T Sivakumar, Abhijit Kosalge. Nano suspensions: A Promising Drug Delivery Strategy. Research J. Pharm. and Tech.2010;3(1):39-44.
7. Pawar Pravin, Yadav Adhikrao, Gharge Varsha. Different Techniques for Preparation of Nano suspension with Reference to its Characterisation and various Applications - A Review. Asian. J. Res. Pharm. Sci. 2018;8(4):210-216.
8. Paun J.S and Tank H.M. Nano suspension: An Emerging Trend for Bioavailability Enhancement of Poorly Soluble Drugs. Asian J. Pharm. Tech. 2012; 2(4):157-168.
9. Atul Phatak, Pallavi Jorwekar, P.D. Chaudhari. Nano suspensions: A Promising Nanocarrier Drug Delivery System. Research J. Pharma. Dosage Forms and Tech. 2011; 3(5):176-182.
10. Rajashri R. Kulkarni, Dipti G. Phadtare, Ravindra B. Saudagar. A Novel Approach Towards Nanosuspension. Asian J. Pharm. Res. 2015;5(4):186-194.
11. Harshil M. Patel, Bhumi B. Patel, Dr. Chainesh N. Shah, Dr. Dhiren P. Shah. Nano suspension Technologies for Delivery of Poorly Soluble Drugs-A Review. Research J. Pharm. and Tech. 2016;9(5): 625-632.
12. Sarika V. Khandbahale. A Review- Nano suspension Technology in Drug Delivery System. Asian J. Pharm. Res.2019;9(2):130-138.
13. V. Rajesh Babu, Aleem M.A, Syeda Rana Nikhat, Sana Aslam, Mohib Khan. Nanosuspension Technology for Poorly Water-Soluble Drugs: An Overview. Research J. Pharm. and Tech.2011; 4(4): 515-520.
14. Deepshikha Sikarra, Vaibhav Shukla, Ankit Anand Kharia, Chatterjee D. P. Journal of Medical Pharmaceutical and Allied Sciences 2012; 01:1-22.
15. Ethiraj T, Sujitha R, Ganesan V. Formulation and In Vitro Evaluation of Nanosuspension of Glimepiride. International Journal of Pharmacy. 2013; 3 (4): 875-882.
16. Suryakanta Nayak, Dibyasundar Panda, Ajaya Kumar Patnaik. Nanosuspension – Preparation, In Vitro and Ex Vivo Evaluations of Felodipine Hydrochloride. Research J. Pharm. and Tech. 2015;8(1):38-43.
17. Steffi PF and Shrinivasan M, “Preparation Characterization and Stabilization of Curcumin Nanosuspension" International Journal of Pharm Tech Research. 2014; 6(2): 842-849.
18. Mane AN, Gilda SS, Ghadge AA, Bhosekar, Bhosale RR. Nanosuspension – A Novel Carrier for Lipidic Drug Transfer. Scholar Academic Journal of Pharmacy.2014; 3(1):80-88.
19. Patravale V.B, Date A.A, Kulkarni R.M. Nanosuspensions: A Promising Drug Delivery Strategy. Journal of Pharmacy Pharmacology. 2004:56(7): 827–840.
20. S.S. Vasava, N.P Choti and H.K. Patel, Formulation And Evaluation Drug Delivery system of Etoricoxib. Pharma Science Monitor 6(1), Jan-Mar 2015,10-27.
21. Mayuri Yadav, Shashikanth D, Prajkta C. Nanosuspension: novel techniques in the drug delivery system. World J Pharm Pharm Sci 2014;3:410-33.
22. Shilpa CP. Nanosuspension-a novel approaches in the drug delivery system. Int Pharm Res Rev 2013;2:30-9.
23. Somasekhar M. Reddy et al., In vitro study of formulation and evaluation of nanosuspension of tamoxifen. IJBCP Vol. No 5.
24. Sonia Gera, Sreekanth Talliri, et al, Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement. AAPS Pharm Sci Tech (2017) DOI: 10.1208/s12249-017-0790-5.
25. Gao L et al., Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement, Drug Dev Ind Pharm.2007 Dec:33(12):1332-9.
26. Sundar V.D, Divya .P, Sridevi.P, Akhila.K, Dhanaraju M.D, Design, Formulation, and Evaluation of Nanosuspension For Drug Delivery of Celecoxib Int.Jr.Pharm.Res. Vol 11(1) 2019, 139-145.
27. Manishaanjane, Shikha Agarwal, Amreen Khan, Formulation and Evaluation of Nanosuspension of Valsartan, Int.J.Curr.Pharm.Res, Vol10(2) 2018,63-74.
28. Y. Padmavathi, Akari Anjali, Nayaka Raghavendra Babu, P Ravi Kumar. Development and validation of new FTIR method for quantitative analysis of Gliclazide in bulk and pharmaceutical dosage forms. Asian J. Research Chem. 2017; 10(3):377-382.
29. Pinderjit S, Rajnish K, Harinder S. Application of UV Spectrophotometric Method for Analysis of Gliclazide in Pharmaceutical Dosage Forms. Int J Pharm Pharm Sci. 2011; 3(4): 259-260.
30. Samina AJ, Snehal PM, Poonam SK, Yogesh VP, et al. Development and Validation of UV Spectrophotometric Method for the Determination of Gliclazide in Tablet Dosage Form. Der Pharma Chem. 2011; 3(4): 338-343. Edition, Pharmaceutical Press, London.
31. Nehal Daebis et al., formulation and characterization of itraconazole oral nanosuspension, Dev drug Cli Tri 1(1):102.
32. Raihanul F, Sharif Md, Alok KP, Mohammad SK, et al., In vitro Release Kinetic Study of Gliclazide from Methocel K100MCR and Methocel K100LVCR, Matrix Tablets. Int J Pharm Tech Res. 2012; 4(2): 883-888.
33. Korsmeyer, Gurny R, Doelker E, Buri P, et al. Mechanisms of Solute Release from Porous Hydrophilic Polymers. Int J Pharm. 1983; 15: 25-35.